Onxeo Announces the Evolution and Reinforcement of Its Board of Directors

Onxeo Announces the Evolution and Reinforcement of Its Board of Directors

clinical development of anticancer agents to Onxeo's promising pipeline.” Prof. Jean-Pierre Kinet, M.D., stated: “With its two lead products under development and an ambitious preclinical program, Onxeo can make a significant contribution to R&D in the …

(Visited 8 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.